These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 15576967)

  • 1. [Effects of calcium channel blockers in atherosclerosis and cardiovascular event and oxidative vascular damage].
    Fujino T; Sumitomo K; Hasebe N; Kikuchi K
    Clin Calcium; 2004 Jan; 14(1):119-27. PubMed ID: 15576967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelium, atherosclerosis and calcium channel blockers.
    Biswas TK
    J Indian Med Assoc; 2003 Jul; 101(7):428-31. PubMed ID: 14748381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Calcium antagonists: current and future applications based on new evidence. Effects of calcium channel blockers on oxidative stress].
    Nishiyama A; Nakano D; Hitomi H
    Clin Calcium; 2010 Jan; 20(1):38-44. PubMed ID: 20048432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Perspective of calcium antagonist].
    Kim-Mitsuyama S
    Clin Calcium; 2005 Jan; 15(1):81-6. PubMed ID: 15632476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current aspects of the mechanism of action of calcium antagonists in patients with diabetes mellitus].
    Kostiuk OP; Zubkova ST
    Fiziol Zh (1978); 1992; 38(3):106-11. PubMed ID: 1499754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes.
    Ceriello A
    Curr Opin Lipidol; 2006 Oct; 17(5):510-8. PubMed ID: 16960499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
    Nakamura K; Yamagishi S; Inoue H
    Med Hypotheses; 2005; 65(1):155-7. PubMed ID: 15893134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity.
    Hof RP; Rüegg UT
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):107S-113S. PubMed ID: 1826999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.
    Ribeiro AB
    Curr Med Res Opin; 2006 Jan; 22(1):1-16. PubMed ID: 16393425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcium antagonists in cardiovascular diseases].
    Thuillez C
    Arch Mal Coeur Vaiss; 1995 Sep; 88 Spec No 4():9-12. PubMed ID: 7503623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New perspectives in cardiovascular medicine: the calcium channel blocking drugs.
    Allert JA; Adams HR
    J Am Vet Med Assoc; 1987 Mar; 190(5):573-8. PubMed ID: 2435691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Calcium antagonists and insulin resistance].
    Higashi Y; Yoshizumi M
    Clin Calcium; 2005 Oct; 15(10):1675-80. PubMed ID: 16199914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Calcium channel blockers and atherosclerosis].
    Hirata K; Yokoyama M
    Clin Calcium; 2004 Jan; 14(1):128-32. PubMed ID: 15576968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiatherosclerotic and vasculoprotective effects of calcium antagonists: clinical implications.
    Ram CV
    J Hum Hypertens; 1990 Dec; 4 Suppl 5():35-9. PubMed ID: 2090836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Calcium antagonists: current and future applications based on new evidence. Classification of calcium channel blockers].
    Takahara A
    Clin Calcium; 2010 Jan; 20(1):24-30. PubMed ID: 20048430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Calcium antagonists: current and future applications based on new evidence. Pleiotropic effects of calcium channel blockers on vascular endothelial function].
    Morimoto Y; Kureishi-Bando Y; Murohara T
    Clin Calcium; 2010 Jan; 20(1):69-75. PubMed ID: 20048436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tissue selectivity of calcium channel blockers].
    Godfraind T
    C R Seances Soc Biol Fil; 1998; 192(1):121-35. PubMed ID: 9759358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention.
    Yamagishi S; Nakamura K; Takeuchi M; Imaizumi T
    Int J Clin Pharmacol Res; 2004; 24(4):129-34. PubMed ID: 15754918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does reversal of oxidative stress and inflammation provide vascular protection?
    Koh KK; Oh PC; Quon MJ
    Cardiovasc Res; 2009 Mar; 81(4):649-59. PubMed ID: 19098298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.